Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EPS without NRIGrowth Rate was -39.10% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -74.70% per year.
During the past 6 years, NewAmsterdam Pharma Co NV's highest 3-Year average EPS without NRI Growth Rate was -39.10% per year. The lowest was -189.10% per year. And the median was -47.90% per year.
NewAmsterdam Pharma Co NV (NAS:NAMS) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
NewAmsterdam Pharma Co NV Earnings per Share (Diluted) Related Terms
NewAmsterdam Pharma Co NV Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for NewAmsterdam Pharma Co NV's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NewAmsterdam Pharma Co NV Earnings per Share (Diluted) Chart
NAMS vs IRON, CLDX, IMNM: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, NewAmsterdam Pharma Co NV's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NewAmsterdam Pharma Co NV PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NewAmsterdam Pharma Co NV's PE Ratio distribution charts can be found below:
* The bar in red indicates where NewAmsterdam Pharma Co NV's PE Ratio falls into.
NewAmsterdam Pharma Co NV Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
NewAmsterdam Pharma Co NV's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.16
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-2.16 mean?
NewAmsterdam Pharma Co NV (NAMS) has a Earnings per Share (Diluted) of $-2.16 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on NewAmsterdam Pharma Co NV and its competitors. According to the industry distribution chart, NewAmsterdam Pharma Co NV ranks #1076 out of 1159 companies in the Biotechnology industry, placing it in the top 92.8%.
Is NewAmsterdam Pharma Co NV's Earnings per Share (Diluted) too high?
NewAmsterdam Pharma Co NV's current Earnings per Share (Diluted) is $-2.16. Based on the distribution chart, NewAmsterdam Pharma Co NV ranks #1076 out of 1159 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NewAmsterdam Pharma Co NV has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NewAmsterdam Pharma Co NV's Earnings per Share (Diluted) compare to IRON and CLDX?
According to the Biotechnology industry distribution chart, NewAmsterdam Pharma Co NV ranks #1076 out of 1159 companies for Earnings per Share (Diluted). This places NewAmsterdam Pharma Co NV in the lower half of its industry. The industry median Earnings per Share (Diluted) is 16.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.20, based on 1,159 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on NewAmsterdam Pharma Co NV and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NewAmsterdam Pharma Co NV's current Earnings per Share (Diluted) is $-2.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewAmsterdam Pharma Co NV stock overvalued right now?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV (NAMS) is currently considered Significantly Overvalued. The stock's GF Value™ is $13.30, compared to a current price of $24.92 — trading 87.4% above its estimated fair value. The current Earnings per Share (Diluted) is $-2.16. NewAmsterdam Pharma Co NV's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For NewAmsterdam Pharma Co NV (NAMS), the current Earnings per Share (Diluted) is $-2.16 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NewAmsterdam Pharma Co NV (NAMS) Overvalued in 2026?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV stock appears to be overvalued.
The current stock price of $24.92 is trading 87.4% above its estimated GF Value™ of $13.30.
GuruFocus considers NewAmsterdam Pharma Co NV to be Significantly Overvalued.
Key valuation signals for NAMS:
Earnings per Share (Diluted): $-2.16
GF Value™: $13.30 vs. price of $24.92 (87.4% above fair value)
No single metric tells the full story. See the NAMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
44GF Score
Get the complete analysis for NAMS
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NAMS has been successfully added to your 
